Vita Therapeutics is a biotechnology company developing state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. The Company is progressing its lead program VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A) with the goal of filing Investigational New Drug Applications with the US Food and Drug Administration in the next 18 months. Long term, the Company is developing its pipeline of cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics is currently working with numerous partners, including PanCella, Wyss Institute, and Johns Hopkins University, to advance their clinical programs. Learn more about the company at www.Vitatx.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/12/22 | $31,000,000 | Series B |
Cambrian Biopharma Cedars-Sinai Medical Center Riptide Ventures Solve FSHD TEDCO | undisclosed |
| 10/12/22 | $31,000,000 | Series B |
Cambrian Biopharma Cedars-Sinai Medical Center Riptide Ventures Solve FSHD TEDCO | undisclosed |
